SECTM1 acts as an immune-related biomarker of poor prognosis and promotes cancer progression by modulating M2 macrophage polarization in esophageal squamous cell carcinoma - Kong, Pengzhou; Jiao, Ye; Sun, Meng; Zhou, Zhinan; Zhang, Yingying; Yang, Xin; Ren, Jing; Yang, Mengyuan; Dong, Yanyan; Song, Bin (Frontiers in Immunology, 2025)